Alexander Beraud

Alexander Beraud serves as a key procurement lead within the National Institute of Allergy and Infectious Diseases (NIAID), managing complex acquisitions that support biomedical research and public health preparedness. He oversees contracts for high-containment laboratory infrastructure, diagnostic technologies, and advanced analytical instrumentation critical to countering emerging infectious threats. His work directly enables NIAID’s mission to accelerate medical countermeasures by ensuring timely access to cutting-edge scientific capabilities and specialized research services. Beraud typically handles competitive sealed bids and negotiated procurements under FAR Part 15, with a focus on R&D, laboratory equipment, and testing services essential to biosafety level 3 and 4 research environments. Beraud maintains longstanding relationships with leading academic and research institutions, including the University of Pittsburgh, Icahn School of Medicine at Mount Sinai, University of Maryland Baltimore, and University of Miami, as well as McLean Hospital Corporation. These partnerships are primarily performance-based, supporting clinical research, infectious disease modeling, and diagnostic validation studies. His contracting approach emphasizes long-term collaboration with institutions possessing specialized biocontainment facilities and translational research expertise, ensuring alignment with NIAID’s strategic priorities in pandemic readiness and immunologic innovation. While the majority of NIAID’s procurements under Beraud’s purview are unrestricted—reflecting the technical specificity and scale of required capabilities—22.6% are set aside for total small business participation under FAR 19.5. This demonstrates a deliberate effort to integrate qualified small businesses in niche technical roles, particularly in equipment calibration, laboratory maintenance, and specialized testing services, without compromising mission-critical performance standards. Beraud’s procurement portfolio is heavily concentrated in NAICS 334516 (analytical laboratory instrument manufacturing) and 541715 (R&D in life sciences), reflecting a focus on high-precision diagnostic tools, biosafety equipment, and computational modeling platforms. He regularly procures next-generation sequencing systems, flow cytometers, and automated biospecimen processing units, underscoring deep technical expertise in life science instrumentation and laboratory automation. His contracting decisions are guided by rigorous scientific requirements and compliance with federal biosafety and data integrity standards.